Univariate analysis of health care elements by graft source and posttransplant time period
| Category . | BMT . | PBSC . | BMT vs PBSC P . | UCB . | BMT vs UCB P . |
|---|---|---|---|---|---|
| Day 0 to 100 | |||||
| Face-to-face visits* | 48 (23-71) | 43 (3-67) | .10 | 40 (2-67) | .02 |
| Total visits | 67.5 (37-95) | 62 (20-87) | .03 | 60 (13-93) | .03 |
| Laboratory studies* | 2448.0 (1896-3710) | 2212.5 (1712-3016) | <.01 | 2960.0 (2335-3883) | <.01 |
| Medications* | 232 (108.5-331.5) | 132 (1-245) | <.01 | 203 (0-359) | .29 |
| RVUs* | 480.7 (372.8-702.2) | 423.2 (294.4-569.3) | <.01 | 466.7 (292.7-689.1) | .23 |
| Day 101 to 365 | |||||
| Face-to-face visit* | 32 (7-88) | 22 (0-61) | .02 | 9 (0-51) | <.01 |
| Total visits* | 63.5 (16-131) | 41.5 (3-96) | .01 | 26 (1-89) | <.01 |
| Laboratory studies* | 1189.5 (302-2667) | 1010 (217-2063) | .11 | 567 (58-2005) | .01 |
| Medications | 76.5 (0-276) | 50 (0-175) | .12 | 31 (0-202) | .06 |
| RVUs | 300.7 (33.4-580.6) | 213.6 (14.9-479.7) | .14 | 174.5 (0-471.9) | .03 |
| Years 1 to 5 | |||||
| Face-to-face visit* | 7 (0-59) | 9 (0-75) | .10 | 1 (0-29) | .43 |
| Total visits* | 14.5 (0-112) | 22 (0-133) | .58 | 6 (0-68) | .12 |
| Laboratory studies* | 82 (0-1205) | 220 (0-2145) | .10 | 75 (0-631) | .43 |
| Medications* | 15.5 (0-161.5) | 38 (0-257) | .09 | 14 (0-100) | .99 |
| RVUs* | 40.7 (0-500.5) | 86.4 (0-510.8) | .37 | 30.3 (0-256.3) | .51 |
| Category . | BMT . | PBSC . | BMT vs PBSC P . | UCB . | BMT vs UCB P . |
|---|---|---|---|---|---|
| Day 0 to 100 | |||||
| Face-to-face visits* | 48 (23-71) | 43 (3-67) | .10 | 40 (2-67) | .02 |
| Total visits | 67.5 (37-95) | 62 (20-87) | .03 | 60 (13-93) | .03 |
| Laboratory studies* | 2448.0 (1896-3710) | 2212.5 (1712-3016) | <.01 | 2960.0 (2335-3883) | <.01 |
| Medications* | 232 (108.5-331.5) | 132 (1-245) | <.01 | 203 (0-359) | .29 |
| RVUs* | 480.7 (372.8-702.2) | 423.2 (294.4-569.3) | <.01 | 466.7 (292.7-689.1) | .23 |
| Day 101 to 365 | |||||
| Face-to-face visit* | 32 (7-88) | 22 (0-61) | .02 | 9 (0-51) | <.01 |
| Total visits* | 63.5 (16-131) | 41.5 (3-96) | .01 | 26 (1-89) | <.01 |
| Laboratory studies* | 1189.5 (302-2667) | 1010 (217-2063) | .11 | 567 (58-2005) | .01 |
| Medications | 76.5 (0-276) | 50 (0-175) | .12 | 31 (0-202) | .06 |
| RVUs | 300.7 (33.4-580.6) | 213.6 (14.9-479.7) | .14 | 174.5 (0-471.9) | .03 |
| Years 1 to 5 | |||||
| Face-to-face visit* | 7 (0-59) | 9 (0-75) | .10 | 1 (0-29) | .43 |
| Total visits* | 14.5 (0-112) | 22 (0-133) | .58 | 6 (0-68) | .12 |
| Laboratory studies* | 82 (0-1205) | 220 (0-2145) | .10 | 75 (0-631) | .43 |
| Medications* | 15.5 (0-161.5) | 38 (0-257) | .09 | 14 (0-100) | .99 |
| RVUs* | 40.7 (0-500.5) | 86.4 (0-510.8) | .37 | 30.3 (0-256.3) | .51 |
Medians and interquartile ranges are displayed.
Significant P value from Kruskal-Wallis test among 3 source groups.